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Despite tremendous successes of GPCR crystallog-
raphy, the receptors with available structures repre-
sent only a small fraction of human GPCRs. An
important role of the modeling community is to maxi-
mize structural insights for the remaining receptors
and complexes. The community-wide GPCR Dock
assessment was established to stimulate and
monitor the progress in molecular modeling and
ligand docking for GPCRs. The four targets in the
present third assessment round presented new and
diverse challenges formodelers, including prediction
of allosteric ligand interaction and activation states in
5-hydroxytryptamine receptors 1B and 2B, and
modeling by extremely distant homology for smooth-
ened receptor. Forty-four modeling groups partici-
pated in the assessment. State-of-the-art modeling
approaches achieved close-to-experimental accu-
racy for small rigid orthosteric ligands and models
built by close homology, and they correctly predicted
protein fold for distant homology targets. Predictions
of long loops and GPCR activation states remain un-
solved problems.
INTRODUCTION
Recent years have been marked by a rapid increase in the num-
ber of experimentally solved structures of G protein coupled re-
ceptors (GPCRs) (Katritch et al., 2013; Venkatakrishnan et al.,
2013), mostly due to technological breakthroughs in membrane
protein crystallization (Bill et al., 2011; Cherezov, 2011; Chun
et al., 2012). However, the receptors with publicly available
structures to date remain only a small fraction of more than
350 non-olfactory/taste GPCRs in the human genome (Fredriks-
son et al., 2003; Lagerstro¨m and Schio¨th, 2008; Ono et al., 2005).
It is an important role of the computational modeling community
to help elucidate the structural details of ligand interactions,
specificity, and function for as many of the remaining receptors
as possible.
The community-wide GPCR modeling and docking (GPCR
Dock) assessment was established to evaluate the progress of1120 Structure 22, 1120–1139, August 5, 2014 ª2014 Elsevier Ltd Almolecular modeling and ligand docking in the context of
GPCRs. While of a philosophy and organization similar to those
of CASP and CAPRI assessments (Kryshtafovych et al., 2014;
Lensink and Wodak, 2010; Moult et al., 2014), GPCR Dock
focuses on specifics of GPCR-ligand complexes as opposed
to the wider structural proteome dominated by soluble and
globular proteins. It thus addresses a different set of challenges,
including distinct intramolecular packing principles influenced
by the native lipid environment of GPCRs, a dynamic conforma-
tional equilibrium, and evolutionally and conformationally vari-
able loops, all of which ultimately affect ligand binding and
function.
During the two assessments conducted in 2008 and
2010, research groups from all over the world were chal-
lenged to predict the details of ligand interactions in the aden-
osine A2A, dopamine D3, and chemokine CXCR4 receptors,
each time using all available experimental information to date
(Kufareva et al., 2011; Michino et al., 2009). These assess-
ments identified 35%–40% sequence identity between target
and template as an empirical cutoff for reliable homology-
based prediction of ligand-receptor interactions and high-
lighted the modeling techniques leading to best prediction
accuracy.
In the year 2013, the third round of the assessment was orga-
nized after the crystal structures of two human 5-hydroxytryp-
tamine (5HT or serotonin) receptors 1B and 2B (5HT1B and
5HT2B, respectively) (Wacker et al., 2013; Wang et al., 2013a)
and a human smoothened homolog receptor (SMO) (Wang
et al., 2013b, 2014) were solved in complex with small molecule
modulators. Modelers were invited to submit their predictions
of complex structures prior to release of the experimental coor-
dinates. The assessment targets spanned a wide range of pre-
diction difficulties, flanked by the 5HT1B receptor on one side,
with transmembrane (TM) domain sequence identity as high
as 48% to the existing structures, and by the SMO receptor
on the other side, with TM sequence identity as low as 14%
and with previously unseen conformations of large extracellular
loops (ECLs). Consequently, the modelers faced a new set
of challenges (compared to previous assessment rounds),
including building a reliable alignment between the target
sequence and the available structural templates, prediction
of long loops, and diverse binding pocket locations. The anal-
ysis of the submitted models highlighted the new successful
computational methodologies and areas still in need of
development.l rights reserved
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GPCRDock2013: Description andSubmission Statistics
The GPCR Dock 2013 assessment was performed for four
ligand-receptor complexes: 5HT1B and 5HT2B, both in complex
with an agonist ergotamine (Wacker et al., 2013; Wang et al.,
2013a) and the TM domain of the human SMO receptor in com-
plex with two distinct small molecule antagonists, LY-2940680
(Wang et al., 2013b) and SANT-1 (Wang et al., 2014). For these
four targets, 181, 171, 88, and 88 unique models were submitted
by 40, 39, 20, and 20 groups, respectively. The list of partici-
pating groups is given in Table 1.
The models were assessed by several criteria evaluating: (1)
the accuracy of alignment of the target sequence to the available
structural templates, (2) the TMbundle structure, (3) the structure
of the extracellular domains and loops, (4 and 5) definition and
geometry of the binding pocket, (6) ligand position, and (7) the
atomic contacts between the ligand and the receptor. The last
two criteria constituted the primary focus of the assessment;
they were converted into a single score representing the likeli-
hood of observing similar deviations among experimentally
solved cocrystal structures (the so-called model ‘‘correctness’’)
and used for final model ranking. All assessment criteria for all
models are reported in Tables S1 and S2 available online. In
the assessment report given in this article, we report the best
model by each assessment criterion, as well as models within
0.1 z-score units, by that criterion, from it.
Target Challenges
TM Homology to Crystallographic Templates
Targets in the GPCR Dock 2013 assessment represented two
extremes on the modeling difficulty scale. The level of sequence
identity of the TM domain of 5HT1B to its highest homology tem-
plates, turkey b1 adrenoreceptor and human dopamine receptor
D3, exceeds 45%, and the corresponding TM domain backbone
root-mean-square deviation (RMSD) values approach 1 A˚ (Fig-
ure 1B), qualifying it as one of the easier homology modeling
cases, approximately the same difficulty as D3 in GPCR Dock
2010 (Figure 1A). The 5HT2B receptor appears slightly more chal-
lenging, with the closest structural template being 41% iden-
tical in the TM domain and the lowest backbone RMSD to the
templates being 1.7 A˚. The third assessment target, however,
represents a challenge previously unseen in GPCR Dock, with
a TM domain sequence identity of less than 15% and significant
structural deviations exceeding, even in the TM domain, 2.7–3 A˚
from any of the structures solved to date.
ECL Challenge
In contrast to the conserved seven-helical fold of the TM do-
mains, the structural repertoire of the ECLs and termini in GPCRs
is highly diverse and, thus, more challenging from the modeling
perspective. Except for highly homologous receptors, GPCR
extracellular domains often have different folds (Figure 1C). In
the serotonin receptor structures, the observed conformations
of ECL2—the longest and the most important of the ECLs due
to its involvement in ligand binding—differ significantly from
any GPCRs solved to date; moreover, there are notable differ-
ences between the two receptor subtypes (Figure 1D). While
the dimensions of ECL2 in the SMO receptor structure coincide
exactly with those of 5HT1B, the three-dimensional (3D) confor-Structure 22, 1120mation of this loop shares more similarity with that of bovine
rhodopsin. The SMO receptor also features an intricately folded
36-residue-long fragment, the so-called extracellular domain
(ECD) linker, which connects TM1 to the extracellular cysteine-
rich domain (CRD; absent from the crystallization construct).
Finally, SMO demonstrates a novel topology of ECL1 and
ECL3, whose lengths (23 and 39 amino acids, respectively) far
exceed those of any other known GPCR structures and whose
conformations are unique in the current GPCR structural uni-
verse (Figure 1D).
Binding Pocket Location
Despite the conserved receptor topology, the compounds and
peptides cocrystallized with GPCRs thus far exhibit remarkable
diversity in their interactions. Because determination of the bind-
ing pocket (i.e., a subset of residues interacting with the ligand) is
a prerequisite for most docking procedures, this variability poses
an additional challenge for the modelers.
For comparing ligand fingerprints in Figure 2A, residue con-
tacts were projected through the alignment onto Ballesteros-
Weinstein indices (Ballesteros and Weinstein, 1995) that were
originally introduced for class A GPCRs and recently extended
to Class F receptors (Wang et al., 2013b). Ergotamine interac-
tions with the 5HT1B and 5HT2B receptors involve two distinct
sites (Figures 2A and 2B): (1) an ‘‘orthosteric’’ site deep in the
TM domain, where ergoline core interactions closely resemble
those observed in other biogenic amine receptors; and (2) an
‘‘allosteric’’ site closer to the ECL region, where the interactions
of the cyclic tripeptide moiety, and especially of the benzyl sub-
stituent, have no analogs among the existing structures and also
differ substantially between 5HT1B and 5HT2B complexes. Even
more pronounced is the difference in the pocket location be-
tween the two SMO receptor complexes and the previously
solved structures of other GPCRs. SANT-1 is mostly occupying
the pocket in the TMdomainmaking extensive contacts with res-
idues in TMs 2, 3, 6, and 7 (Figures 2A and 2C) and in the ECL2
that is submerged deeply in the binding pocket similarly to
rhodopsin. In contrast, LY-2940680makes themajority of its res-
idue contacts in ECL2 and ECL3 with little to no contacts in TMs
3 or 6. The unique contact fingerprints of SANT-1, and especially
LY-2940680, make it impossible to infer the pocket locations by
homology.
Activation State
A part of the serotonin receptor challenge was prediction of the
receptor activation states. Ergotamine is a classical full agonist
of 5HT1B but a biased agonist of 5HT2B, eliciting full b-arrestin-
mediated response but only partial G protein activation. Corrob-
orating its functional selectivity profile, the crystallographic
conformation of 5HT1B with ergotamine has signatures of a clas-
sical active state and closely resembles the active conformation
of b2AR (Rasmussen et al., 2011; Wacker et al., 2013), while the
conformation of 5HT2B is more consistent with an inactive state
in the TM5-TM6 region but an active state in the TM7.
Model Alignment Accuracy
Establishing a residue correspondence between the target
sequence and the homologous structures is a prerequisite for
any homology modeling procedure. Although the complemen-
tary ab initio modeling approaches do not require the alignment
as such, they still rely on identification of structural elements,–1139, August 5, 2014 ª2014 Elsevier Ltd All rights reserved 1121
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OxfordBiochem (0336) Phil Biggin Department of Biochemistry, University of Oxford, UK philip.biggin@bioch.ox.ac.uk
KoreaU (0606) Minsup Kim Department of Bioinformatics, Korea University, Sejong, Korea artcho@korea.ac.kr
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GA, USA
zara.a.sands@gmail.com
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Albuquerque, NM, USA
cbologa@salud.unm.edu
Cristian G. Bologa (2)* (2) Institute of Chemistry, Romanian Academy, Timisoara, Romania
Copenhagen-Norn (1218) Christoffer Norn University of Copenhagen, Denmark christoffer.norn@sund.ku.dk
LSU (1457) Michal Brylinski Louisiana State University, Baton Rouge, LA, USA michal@brylinski.org
GaTech (1458) Jeffrey Skolnick Georgia Institute of Technology, Atlanta, GA, USA skolnick@gatech.edu
Uppsala (1605) Henrik Kera¨nen (1) (1) Department of Cell and Molecular Biology, Uppsala University, Uppsala, Sweden hugo.gutierrez@icm.uu.se
Bart E. Lenselink (2) (2) Division of Medicinal Chemistry, Leiden Academic Centre for Drug Research, Leiden
University, Leiden, the Netherlands
Gerard van Westen (3) (3) ChEMBL Group, European Molecular Biology Laboratory European Bioinformatics
Institute (EMBL-EBI), Hinxton, UK
John P. Overington (3)
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Copenhagen-Gloriam (2128) Vignir Isberg Department of Drug Design and Pharmacology, University of Copenhagen david.gloriam@sund.ku.dk
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Thomas M. Lehto
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University, Pune, India
anirbang@cdac.in
Uddhavesh Sonavane
Rajendra Joshi*
Howard (3007) Jie Xia (1, 2) (1) State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical
Sciences, Peking University, Beijing, China
x.simon.wang@gmail.com
Jui-Hua Hsieh (3) (2) Molecular Modeling and Drug Discovery Core for the District of Columbia
Developmental Center for AIDS Research (DC D-CFAR), Laboratory of Cheminfomatics
and Drug Design, Department of Pharmaceutical Sciences, College of Pharmacy,
Howard University, Washington, DC, USA
Liangren Zhang (1) (3) Molecular Toxicology and Informatics Group, National Institute of Environmental
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Fe´de´rale de Lausanne (EPFL), Lausanne, Switzerland
yuanshg@gmail.com
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Table 1. Continued
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Numbers in parentheses next to participant names indicate the specific affiliations of authors within a group. Asterisks indicate principal investigators.
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Figure 1. Difficulty of GPCR Dock Assessment Targets
(A and B) Sequence and structural similarity of target TM domains to the structures available at the time of the 2008, 2010, (A) and 2013 (B) assessments are
shown. Each dot represents a pair of a GPCRDock target and a PDB template. Higher TM backbone RMSD (x axis) and lower sequence identity (y axis) indicate a
more challenging modeling case. For receptors with multiple X-ray structures, the lowest RMSD to the assessment target is plotted.
(C and D) Topology and conformation of the ECLs in previously solved structures (C) and the three 2013 assessment targets (D).
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Figure 2. Ligand Challenges in GPCR Dock
(A) Contact strength fingerprints of the ligands on the receptor residues in the GPCR Dock 2008, 2010, and 2013 targets.
(B and C) 2013 target contacts in 3D. 5HT1B and 5HT2B interactions with ergotamine are color coded magenta and cyan, respectively; ribbon not displayed for
TMs 6 and 7. SMO residue contacts with LY-2940680 and SANT1 are color coded blue and orange, respectively; ribbon not displayed for TM7. Only residue
contacts with cumulative strength above 1 are depicted. NC, no contact. For the Smoothened receptor, one of two possible Ballesteros-Weinstein numberings in
TM7 is arbitrarily chosen.
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2013 GPCR Modeling and Docking Assessmentsuch as TM helices or loops, within the sequence. Alignment in-
accuracies as small as a one-residue shift in a single helix inev-
itably lead to spatial misplacement of residues in the model and
disruption of correct intra- and intermolecular contacts.
We constructed a structure-based alignment of the TM do-
mains in the assessment targets to all available structural tem-
plates. The obtained residue correspondence is straightforward
for the 5HT1B and 5HT2B receptors, but somewhat ambiguous
for the SMO receptor whose TM7 can be aligned with the corre-
sponding parts in class A receptor structures in two possible
ways differing by one helical turn. Next, a structure-based align-
ment of eachmodel to all available structural templates was built
and compared to the ‘‘correct’’ alignment in the TM region. The
obtained alignments coincided precisely for the majority of the
5HT1B and 5HT2B models, but had one or more mismatches
for the majority of the SMO models (Figures 3A–3C). At least
one of the TM helices 1, 2, 4, 5, 6, and 7 was shifted by one to
four residues in most cases (TM3 homology appeared to be
stronger so most groups aligned it correctly); in some models
the shift was as large as 30 residues (Table S1). The fewest align-Structure 22, 1120ment errors were observed in SMO receptor models by groups
GaTech (a one-residue shift in part of TM5), UWash (a one-
residue shift in TM7), INRIA (one-residue shifts in each of TMs
5, 6, and 7), UMich-Zhang (a three-residue shift in TM6 and a
one-residue shift in TM7), COH-Vaidehi (one-residue shifts in
parts of TMs 5 and 6), and SNU (three-, two-, one-, and one-res-
idue shifts in TMs 1, 2, 5, and 7, respectively).
As described in the Supplemental Experimental Procedures,
the successful alignments were obtained with the use of pro-
file-profile comparisons, 3D model input via threading, or their
combination, as opposed to purely sequence-based alignment
methods such as BLAST or Clustal W. Groups used such pack-
ages as HHSEARCH (So¨ding, 2005), FUGUE (Shi et al., 2001),
RaptorX (Peng and Xu, 2011), SPARKS-X (Zhou and Zhou,
2004), I-TASSER (Roy et al., 2010), or the meta-threading pack-
age LOMETS (Wu and Zhang, 2007). The only accurate align-
ment (that by COH-Vaidehi) obtained by Clustal W (Larkin
et al., 2007) was built in conjunction with secondary structure
prediction via PSIPRED (McGuffin et al., 2000) and manual
adjustments to achieve agreement with experimental residue–1139, August 5, 2014 ª2014 Elsevier Ltd All rights reserved 1127
(legend on next page)
Structure
2013 GPCR Modeling and Docking Assessment
1128 Structure 22, 1120–1139, August 5, 2014 ª2014 Elsevier Ltd All rights reserved
Structure
2013 GPCR Modeling and Docking Assessmentmutagenesis (Dijkgraaf et al., 2011). In contrast, the procedure
used by UMich-Zhang was fully automatic but still resulted in
one of the most accurate target-template alignments in the
SMO assessment. Threading and profile comparisons have,
therefore, proved their usefulness in recognition of distant ho-
mology for GPCRs.
TM Bundle Structure Prediction
The accuracy of prediction of TM bundle geometry was
assessed by measuring the RMSD of the backbone atoms in
the models following their optimal superposition with the corre-
sponding atoms in the answers. The conserved heptahelical
topology in GPCRs facilitates the prediction of this domain; how-
ever, ambiguities may arise due to residue insertions or deletions
leading to helical kinks and bulges, as well as due to large varia-
tions in the length of the loops connecting the helices, leading to
displacement of the helix ends.
Among 5HT1B predictions in GPCRDock 2013, themedian TM
bundle RMSD to the answer was 1.89 A˚, with the lowest values
achieved by groups COH-Vaidehi (model #5, 1.52 A˚), UWash
(model #1), and EPFL (model #3) (Figure 3D–3F; Table S1).
5HT2B predictions had the median TM domain RMSD of
2.14 A˚, with the best accuracy achieved by group NCATS
(model #3, also 1.52 A˚). The median TM bundle RMSD for the
SMO receptor was 6.33 A˚, with the lowest values achieved by
group GaTech (SMO/SANT-1 models #1–#5, from 2.78 A˚ to
3 A˚; SMO/LY-2940680 models #1–#5, from 2.97 A˚ to 3.04 A˚)
and UWash (SMO/LY-2940680 model #4, 3.29 A˚). Errors in
the sequence alignment led to significant geometry prediction
inaccuracies.
Most successful TM predictions for the serotonin receptors
were obtained by homology with the existing aminergic receptor
structures using Modeler (Eswar et al., 2006). Models were
selected by either one of the Modeler energy functions (EPFL,
NCATS) or manually (COH-Vaidehi, NCATS). UWash generated
their models for all three receptors by homology with multiple
templates and by fragment assembly with de novo sampling of
unaligned regions in RosettaCM. Group GaTech did not provide
the description of their modeling methods.
We compared the achieved prediction accuracy with the
so called ‘‘naı¨ve’’ approach based on threading the target
sequence through the coordinates of a homologous experi-
mental structure. From this perspective, the level of accuracy
of the best 5HT2B prediction (1.52 A˚) is remarkable, given that
the TM domain of the closest experimentally solved structure,
that of dopamine receptor D3 (Protein Data Bank [PDB] 3PBL),
has a higher backbone RMSD of 1.7 A˚. In the cases of 5HT1B
and SMOmodels, the predictions were no closer to the answers
than the best homology modeling templates (b2AR, PDB 3NY9,
with the TM backbone RMSD of 1.19 A˚ to 5HT1B; and CXCR4,
PDB 3OE8, with the TM backbone RMSD of 2.74 A˚ to SMO).Figure 3. Protein Structure Prediction in GPCR Dock 2013
(A–C) Sequence alignment errors observed in the submitted models of 5HT1B, 5H
line. TM helices 1 through 7 are shown on the horizontal axis; the vertical shift of a
corresponding TM helix.
(D–F) Scatterplot of TM domain backbone RMSD (horizontal) versus ECL2 bac
receptors.
See also Table S1.
Structure 22, 1120Of particular interest was the activation state in the 5HT recep-
tormodels. GPCR activation is a complex process involving helix
movement and deformations, and switching side chain rotamers
(Audet and Bouvier, 2012; Katritch et al., 2013; Nygaard et al.,
2009). For the sake of the present analysis only, we chose the
rotation angles of TMs 6 and 7 with respect to a rigid block of
TMs 3 and 4 as quantitative indicators of activation (Figure 4A).
The Cb atoms of residues in Ballesteros-Weinstein positions
6.44 and 7.46 were chosen as the reference points for TMs 6
and 7, respectively, because their orientation relative to other he-
lices is known to reflect the degree of total and biased activation
(Wacker et al., 2013). In the majority of GPCR active-state struc-
tures solved to date, TM6 and TM7 are rotated and displaced
from their inactive state positions in a correlated fashion (Fig-
ure 4B). This is also the case for the 5HT1B/ergotamine structure
that is found in the classical active state with TM6 and TM7
angles measuring 26 and 18, respectively (Figure 4C). The
5HT2B/ergotamine complex, however, is different, as its TM6
rotation is more consistent with an inactive state (12) while
TM7 rotation is clearly active (32). This unique feature makes
5HT2B an outlier in the plot on Figure 4B and creates an unprec-
edented challenge for modelers.
Quite encouragingly, conformations of TM6 and TM7 were
consistent with the target activation state for a large number of
5HT1B models (Figure 4D). In most cases, the correct conforma-
tion was inherited from an active-state homology template such
as b2AR (Rasmussen et al., 2011); however, at least two groups,
NIID and Caltech-Poland-CSMC, achieved it by explicit large-
scale sampling of the helical bundle. In contrast to 5HT1B, the
activation state of 5HT2B was not captured in any of the 5HT2B
models (Figure 4E). Instead, the prediction closest to the
observed biased state of 5HT2B is found among 5HT1B models
(models #4 and #5 by the group Caltech-Poland-CSMC).
Although the recent X-ray structures shed light on the mecha-
nistic principles of GPCR activation, these principles have yet
to propagate into the modeling methods and applications.
Extracellular Domain Prediction
The prediction of ECL conformations in the two serotonin
receptors was facilitated by the presence of homologous similar
length loops in the existing experimental GPCR structures. ECL1
that has the length of 10 and 11 residues in the two receptors,
respectively, was predicted in 31 5HT1B models by 18 groups
with backbone RMSD of 1.06 to 2 A˚, and in 11 5HT2B models
by 6 groups with backbone RMSD of 1.34 to 2 A˚ (Table S1).
More than 50% of ECL1 atomic contacts with the environment
were predicted correctly in 21 5HT1B models by 10 groups and
in 60 5HT2B models by 20 groups (data not shown).
ECL2 which is partially disordered in both 5HT1B and 5HT2B
structures was predicted with much lower accuracy: the best
ECL2 backbone RMSD for the experimentally resolved part ofT2B, and Smoothened receptors. Each model is represented by a continuous
line with respect to the axis indicates the average error in the alignment of the
kbone RMSD (vertical) for the predictions of 5HT1B, 5HT2B and Smoothened
–1139, August 5, 2014 ª2014 Elsevier Ltd All rights reserved 1129
Figure 4. Quantitative Evaluation of GPCR Activation States
(A) The canonical activation process involves rotation of TM6 and TM7 around the axis of TM3, with rotation angles being characteristic of the degree of activation.
(B) Scatterplot of TM6/TM7 rotation angles in the experimentally solved GPCR structures.
(C) Canonical and biased activation states observed in 5HT1B and 5HT2B structures.
(D and E) TM6-TM7 rotation angles in the serotonin receptor models.
See also Table S1.
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2013 GPCR Modeling and Docking Assessmentthe loop exceeded 3.7 A˚ for 5HT1B and 3.9 A˚ for 5HT2B models
(Figures 3D–3F; Table S1). This was despite the fact that, in the
majority (120 5HT1B and 97 5HT2B) of models, the ECL2-TM3
disulfide bridge was captured correctly.
ECL3was partially disordered in the 5HT1B structure, making it
impossible to compare the predictions to it; the corresponding
13-residue loop in 5HT2B was predicted with backbone RMSD
between 2.27 and 3 A˚ in 11 models by 6 groups (Table S1). In
some cases, the loop displacement was associated with inaccu-
rately predicted positions of the extracellular ends of the TM
helices, while the backbone conformation of the loop was cor-
rect. Consistent with this observation, more than 50% of the
loop contacts with its atomic environment were captured
correctly in 64 models by 17 groups (data not shown). The
ECL3 conformation and the orientation of the two cysteine
residues in it (C340 and C344 in 5HT1B; C350 and C353 in
5HT2B) were favorable for the disulfide bridge formation in 67
5HT1B and 59 5HT2B models.
Unfortunately, modeling of long loops or termini with no ho-
mology to the existing structures remains an unsolved problem.
None of the SMO models predicted the geometry of ECD linker
(36 residues), ECL1 (23 residues), or ECL3 (39 residues) with
acceptable accuracy: the lowest backbone RMSD after the1130 Structure 22, 1120–1139, August 5, 2014 ª2014 Elsevier Ltd Aloptimal superposition of the TM domain exceeded 12 A˚, 8 A˚,
and 7 A˚ for the ECD linker, ECL1, and ECL3, respectively (Table
S1). None of the models captured the intra-ECD-linker disulfide
bond (C193–C213) or the disulfide connecting the linker to
ECL1 (C217–C295). However, it was an encouraging finding
that the helical fold and the disulfide bond in the ECL3 (C490–
C507) were correctly predicted in 12 models submitted by
groups UWash (SMO/LY-2940680 models #1, #4, and #5;
SMO/SANT-1 models #4 and #5), Warsaw (SMO/LY-2940680
models #1, #3, and #5; and SMO/SANT-1 models #1, #3, and
#5), and Vanderbilt (SMO/SANT-1 model #4).
ECL2 modeling in SMOwas facilitated by its structural similar-
ity to the corresponding fragment of bovine rhodopsin: when the
TM domains are optimally superimposed, the backbone RMSD
of the 19 ECL2 residues equals 3.21 A˚. Group UWash modeled
SMO ECL2 with RMSD of around 3 A˚ (2.92 A˚ for model #1 and
3.53 A˚ for model #4); 3.68 A˚ and 3.76 A˚ were achieved by group
UMich-Zhang. For both of these groups, the initial target-tem-
plate sequence alignment appears to have only minor errors,
all localized to TM6 and TM7. Also, group Helsinki-Xhaard
achieved the ECL2 RMSD of 3 A˚ in their model #5 of the SMO/
SANT-1 complex, despite generally inaccurate target-template
sequence alignment; this was due to the fact that their TM3,l rights reserved
Figure 5. Scatterplot of Binding Pocket Heavy Atom RMSD versus
the Accuracy of Prediction of Ligand Pocket Fingerprint for the
Models of the Four Target Complexes in GPCR Dock 2013
(A–D) The binding pocket heavy atom RMSD (horizontal axis) is plotted versus
the accuracy of prediction of ligand pocket fingerprint (vertical axis) for the
models of the four target complexes in GPCRDock 2013, 5HT1B (A), 5HT2B (B),
SMO/LY (C), and SMO/SANT1 (D).
See also Table S2.
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Structure 22, 1120TM4, and TM5 alignment was correct and the large alignment
shifts were localized elsewhere. On the contrary, some models
with few alignment errors failed to predict the loop geometry.
The conserved ECL2-TM3 disulfide bond (C314–C390) was
correctly predicted in 70 of the 176 models of SMO complexes.
TM domain prediction accuracy did not correlate with ECL
prediction accuracy, except for the fact that most accurate
predictions in both categories were produced based on an
alignment with the least errors. Thus, we also assessed the
model population by the combined accuracy of TM domain
and ECL2 prediction (ECL2 was chosen over other extracellular
regions because of its importance in ligand binding). Indepen-
dent z-scores were calculated for TM and ECL2 backbone pre-
dictions after eliminating negative outliers (models deviating
from the mean by more than 2 SDs) and averaged. The highest
accuracy models differed from the respective population means
by 1.12 (Copenhagen-Gloriam 5HT1B models #1 and #2), 1.38
(UMich-Zhang 5HT2B model #3), 1.33 (UWash SMO/LY-
2940680 model #1), and 1.44 (UMich-Zhang SMO/SANT-1
model #2) SDs.
Group Copenhagen-Gloriam built their serotonin receptor
models with Modeler using hybrid templates and selected the
best solutions by Modeler DOPE score and visual inspection.
For all three of the assessment target receptors, UMich-Zhang
used a composite approach including profile-profile compari-
sons, threading, and iterative fragment reassembly with conse-
quent model refinement at the atomic level using fragment-
guided molecular dynamics simulation (Zhang et al., 2011).
UWash generated their models by homology with multiple tem-
plates and by fragment assembly with de novo sampling of un-
aligned regions in RosettaCM. Table S1 shows models ranked
by their combined protein prediction z-scores.
Binding Pocket Definition and Geometry
The correctness of the binding site residue selection and the
local accuracy of the binding site geometry only weakly correlate
with the overall structural accuracy of the model but are much
more important for ligand docking and screening applications.
We therefore evaluated these parameters separately. The cor-
rectness of the binding site residue identification was assessed
by calculating the ligand contact strength fingerprint on the
model residues and comparing it with the corresponding finger-
print in the target structure. The RMSD of the binding site resi-
dues was used to assess the geometrical accuracy of the pocket
and calculated using the optimal superposition of the TM
domains.
The RMSD of the binding site residues was as low as 1.31 A˚ for
the 5HT1B predictions (achieved in model #3 by group Stock-
holm-Carlsson) (Figure 5; Table 2). This model also featured as
high as 81.1% accuracy in the ligand fingerprint determination.
Models #2 and #4 by the same group also had very low binding
site RMSD but were less accurate in the ligand fingerprint deter-
mination. A similar situation was observed in models #1, #2, and
#4 by group Copenhagen-Gloriam. The median binding site
RMSD among the 5HT1B models was 2.35 A˚, and the median
fingerprint accuracy was 57%.
Group Stockholm-Carlsson also produced the most accurate
predictions of the binding site location (79.4% in model #2, with
pocket residue RMSD of 1.94 A˚) and geometry (1.88 A˚ in model–1139, August 5, 2014 ª2014 Elsevier Ltd All rights reserved 1131
Table 2. Top Predictions in the GPCR Dock 2013 Assessment
Group Model
Mean TM
Alignment
Error, No. of
Residues
TM RMSD, A˚
(No. of Residues)
TM
Qsuper, %
ECL2
RMSD, A˚
(No. of
Residues)
Protein
prediction
Z Score
Pocket
RMSD, A˚
(No. of
Residues)
Pocket
Prediction
Accuracy, %
Ligand
RMSDa, A˚
Contact
Strength
Prediction
Accuracya, % Correctnessa,b, %
5HT1B/Ergotamine
Stockholm-Carlsson 2 0 1.82 (190) 65 4.34 (13) 0.86 1.41 (19) 77 1.51 (1.9) 47 (44) 3.35 (2.29)
Stockholm-Carlsson 3c 0 1.66 (190) 69 5.49 (13) 0.7 1.31 (19) 81c 2.09 (1.22) 51 (55) 2.77 (5.69)
Warsaw 3 0 1.78 (190) 66 4.85 (13) 0.74 1.47 (19) 72 2.03 (2.25) 39 (35) 1.76 (1.31)
Warsaw 1 0 1.78 (190) 66 4.85 (13) 0.74 1.47 (19) 72 2.1 (2.4) 40 (38) 1.75 (1.4)
Copenhagen-Gloriam 2d 0 1.68 (190) 70 4.09 (13) 1.12d 1.38 (19) 66 2.45 (2.07) 39 (39) 1.37 (1.74)
UCBPharma-Pitt 2 0 1.78 (190) 66 6.36 (13) 0.27 1.51 (19) 73 2.67 (1.56) 41 (43) 1.33 (2.73)
COH-Vaidehi 5 0 1.52 (190) 77 7.44 (13) 0.26 2.56 (19) 74 1.57 (1.94) 27 (29) 1.25 (1.19)
LMC-Monash 2 0 2.18 (190) 64 4.71 (13) 0.27 2.49 (19) 71 2.97 (3.4) 39 (35) 1.06 (0.74)
PompeuFabra 2 0 1.72 (190) 67 5.2 (13) 0.71 2.48 (19) 66 2.86 (1.34) 36 (57) 1.02 (5.85)
PompeuFabra 1 0 1.73 (190) 67 4.89 (13) 0.8 2.01 (19) 65 2.61 (2.68) 33 (39) 1.01 (1.23)
Schro¨dinger 1e 0 1.98 (190) 68 5.18 (13) 0.38 1.56 (19) 69 5.27 (0.72) 36 (65) 0.31 (13.01e)
5HT2B/Ergotamine
Warsaw 3 0 2.12 (191) 61 5.54 (19) 0.46 2.69 (23) 76 1.05 (1.07) 50 (64) 5.11 (9.56)
MerzPharma 3 0.23 2.68 (191) 55 9.79 (19) 1.04 5.46 (23) 68 1.14 (0.68) 45 (68) 3.92 (15.57)
MerzPharma 2e 0.21 2.68 (191) 55 9.81 (19) 1.04 5.49 (23) 68 1.37 (0.66) 45 (73) 3.37 (19.69e)
MerzPharma 1 0.23 2.69 (191) 54 9.85 (19) 1.06 5.51 (23) 67 1.39 (0.76) 44 (73) 3.15 (17.73)
Stockholm-Carlsson 2c 0 2.16 (191) 59 6.32 (19) 0.27 1.94 (23) 79c 1.64 (1.74) 45 (44) 2.82 (2.56)
Copenhagen-Norn 1 0 2.38 (191) 54 7.51(19) 0.24 3.81(23) 63 1.58 (1.72) 41 (47) 2.5 (2.97)
Stockholm-Carlsson 4 0 2.26 (191) 61 4.39 (19) 0.5 1.88 (23) 77 2.46 (1.11) 53 (66) 2.37 (10.04)
Padova 2 0 2.03 (191) 62 8.74 (19) 0.01 4.36 (23) 69 2.45 (1.38) 43 (65) 1.64 (7.71)
UCBPharma-Sands 4 0 2.75 (191) 63 4.55 (19) 0.17 2.65 (23) 74 2.81 (2.46) 44 (49) 1.38 (2.08)
PompeuFabra 4 0 2.07 (191) 61 8.83 (19) 0.07 3.46 (23) 73 2.09 (1.8) 34 (47) 1.36 (2.79)
PompeuFabra 5 0 2.07 (191) 61 6.74 (19) 0.3 3.65 (23) 75 2.29 (2.49) 35 (49) 1.27 (2.03)
LMC-Monash 2 0 3.04 (191) 47 6.08 (19) 0.82 3.83 (23) 67 2.73 (1.87) 40 (50) 1.25 (3.04)
UMich-Zhang 3d 0 1.63 (191) 65 3.94 (19) 1.38d
SMO/LY-2940680
Vanderbilt 3 1.35 5.36 (189) 18 14.34 (19) 0.05 13.85 (21) 5 4.42 2 0.12
GaTech 4f 0.13f 2.97 (189) 38 6.61 (19) 1.04
UWash 1d 0.2 3.86 (189) 37 2.92 (19) 1.33d
SNU 1c 0.86 4.16 (189) 21 14.27 (19) 0.16 10.99 (21) 25c
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Structure 22, 1120#4) in the 5HT2B assessment. The median values were 58.7%
and 3.42 A˚, respectively.
Both groups (Stockholm-Carlsson and Copenhagen-Gloriam)
built their predictions using Modeler (Eswar et al., 2006) with
hybrid templates (b1AR, b2AR, D3, and H1 receptors). A critical
step in the Stockholm-Carlsson modeling procedure was
assessment of the models by virtual ligand screening (VLS)
enrichment, in iterative manner. Alternatively, Copenhagen-Glo-
riam prioritized their predicted compound poses by agreement
with other aminergic GPCRs, ligand structure-activity relation-
ship (SAR), and mutation and other species data. Both groups
manually inspected their models at the final selection step.
The predictions for the SMO receptor complexes were far
less accurate (Figure 5; Table 2). The best pocket RMSD among
the SMO/LY-2940680 predictions was equal to 9.06 A˚ (model
#5 by group GaTech); median, 13.28 A˚. The highest pocket
fingerprint accuracy was only 25% (model #1 by group SNU);
median, 10.7%. However, the binding site predictions were
considerably more accurate for the SMO/SANT-1 complexes
with the lowest pocket RMSD of 4.63 A˚ (model #2 by group
UMich-Zhang) and the best binding site location accuracy of
58.9% (model #5 by group GaTech). The binding mode of the
SANT-1 molecule involves fewer ECL contacts and more
closely resembles the previously observed binding models of
agonists and antagonists in other GPCRs, possibly contributing
to better predictions of both pocket location and geometry in
the SMO/SANT-1 assessment in selected models. The median
values for pocket RMSD and location accuracy were 10.66 A˚
and 15.8%, respectively.
Understandably, top ranking predictions for SMO were ob-
tained in the models with fewest alignment errors. Group SNU
docked the ligands with GalaxyDock (Shin et al., 2013) and per-
formed manual mutagenesis-guided ligand pose selection.
Group UMich-Zhang identified the binding sites by a combina-
tion of binding-specific substructure comparisons and sequence
profile alignments (the so-called COACH; Yang et al., 2013b). To
generate ligand-GPCR complexes, they used a low-resolution
coarse grain docking method, BSP-SLIM (Lee and Zhang,
2012), that recognizes local shape and feature complementar-
ities between the ligand and the binding pocket.
Ligand RMSD and Ligand-Pocket Contacts
The main focus of the assessment for the serotonin receptor tar-
gets was prediction of the binding pose of the ligand and its con-
tacts with the surrounding residues. For the 5HT1B/ergotamine
complex, the median ligand RMSD was 5.44 A˚, with the best
result as low as 1.51 A˚ (Figure 6A; Table 2; Table S2). Themedian
contact prediction accuracy was equal to 15.1%, the best being
51.1%. The best RMSD and the best contact prediction were
achieved in models #2 and #3, respectively, by group Stock-
holm-Carlsson. The corresponding statistics for the 5HT2B re-
ceptor were as follows (Figure 6B; Table 2; Table S2): the median
ligand RMSD of 5.54 A˚ (Table 2); best, 1.05 A˚ (achieved in model
#3 by group Warsaw); the median contact accuracy of 17.8%;
best, 53.1% (achieved in model #4 by group Stockholm-Carls-
son). The most accurate models were generally accurate by
both criteria, RMSD and contacts.
Because the goal of molecular modeling is to ultimately com-
plement the experimental structure determination efforts, it was–1139, August 5, 2014 ª2014 Elsevier Ltd All rights reserved 1133
Figure 6. Ligand Prediction for the Targets in the GPCR Dock 2013 Assessment
(A–D) Prediction of ligand pose and ligand pocket contacts. The shaded background represents the experimentally observed distribution of the parameters on the
plot. Solid black curves represent isolines of the model ‘‘correctness’’ used for model scoring and ranking.
(E–H) Scatterplot of ligand correctness plotted against the RMSD of binding pocket residues.
In (A), (B), (E), and (F), predictions for the ergoline core and the TM part of the binding pocket are shown in light pink and light cyan for 5HT1B and 5HT2B,
respectively.
See also Table S2.
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2013 GPCR Modeling and Docking Assessmentinteresting to compare the achieved levels of accuracy to the
variation observed in the crystallographic experiments and re-
sulting from the natural protein flexibility and/or limited experi-
mental resolution. Using a large set of pairs of PDB complexes
of identical protein/ligand composition, we derived statistics for
answering this question (Figure S1; Supplemental Methods).
According to our calculations, the accuracy of the best models
corresponded to only 3.35% of the experimental distribution for
5HT1B and to 5.11% for 5HT2B (Table 2; Table S2). We further
refer to these percentiles as the measure of ‘‘correctness’’ of
the models.
The aforementioned results show that the 2013 serotonin
receptor ligand prediction accuracy was slightly below that1134 Structure 22, 1120–1139, August 5, 2014 ª2014 Elsevier Ltd Alachieved in 2010 for the D3/eticlopride complex (0.96 A˚
RMSD with 58% of contacts, correctness of 8.09%). However,
it would be incorrect to conclude that the computational
modeling field has not progressed, because the complexity of
the ligand docking problem in the present assessment was
much higher. As described earlier, ergotamine simultaneously
occupies orthosteric and allosteric pockets in the target recep-
tors. Extensive and diverse contacts in the ECL regions create
an additional modeling challenge that was not a part of the
2010 D3 assessment. To quantitatively estimate the progress,
we evaluated the quality of predictions for the orthosteric part
of the ergotamine molecule, i.e., its ergoline core (Table S2).
For 5HT1B, the median ergoline core RMSD was 3.94 A˚, andl rights reserved
Figure 7. Distribution of Model Correctness by Confidence Ranks
Assigned to the Models by the Authors
The distribution of model correctness by confidence ranks assigned to the
models by the authors in each of the core assessments 5HT1B (A), 5HT2B (B),
SMO/LY-2940680 (C), and SMO/SANT-1 (D) are shown.
See also Figure S1 and Table S2.
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2013 GPCR Modeling and Docking Assessmentthe best result was as low as 0.72 A˚ (achieved in model #1 by
group Schro¨dinger). The median contact prediction accuracy
was 22.9%, and the best was as high as 65.3% (model #3 by
group Copenhagen-Norn). For 5HT2B, the median ergoline
core RMSD was equal to 3.69 A˚, the best being 0.64 A˚ (model
#2 by group NCATS). The median contact accuracy equaled
23.9%, with the best achieving 72.6% (model #2 by Merz-
Pharma). This level of accuracy places the ergoline core predic-
tions in the shaded area of the ligand RMSD/contact plot in Fig-
ure 6, which represents the experimental variation of theStructure 22, 1120corresponding parameters. The correctness of the best ergo-
line core predictions corresponds to 13.01% and 19.55% of
the experimental distribution in the 5HT1B and 5HT2B assess-
ments, respectively.
The most accurate 5HT1B ligand predictions also featured a
low RMSD of the binding pocket residues (Figure 6E). However,
the correlation was not as straightforward for 5HT2B complexes,
as some accurate ligand predictions were achieved in relatively
inaccurate pockets. A closer inspection of the models showed
that the pocket inaccuracies in thesemodels were of local nature
and observed either in the ECL2 residues or in a single incorrectly
aligned TM helix (for the models by MerzPharma).
Far less accurate predictions weremade for the SMO receptor
complexes (Figures 6C and 6D; Table 2; Table S2). The lowest
ligand RMSD for SMO/LY-2940680 complex models was as
high as 4.42 A˚ (model #3 by group Vanderbilt), and the highest
achieved contact ratio was only 8.8% (model #1 by the same
group). Due to the more ‘‘traditional’’ location of the binding
site in the SMO/SANT-1 complex, the accuracy was marginally
better for this target: the lowest RMSD of 4.31 A˚ (model #5 by
group GaTech) and the best contact ratio of 12.3% (model #5
by group SNU). The median ligand RMSD exceeded 10 A˚, and
the median fraction of contacts was less than 1% for both
SMO receptor complexes. In the context of experimental varia-
tion, these values correspond to approximately 0.1% percentile
of the distribution (Table S2). Unlike in the serotonin receptor
models, no correlation was observed between RMSD and con-
tacts in the SMO predictions.
By the rules of the assessment, the participants submitted the
maximum of five models for each target and ranked these
models according to the degree of their confidence in the cor-
rectness of the prediction. As in the 2010 assessment, no corre-
lation was observed between the rank and the accuracy of the
models (Figure 7).
Analysis of Best Models
Two 5HT1B and seven 5HT2B models stood out as their ligand
prediction accuracy brushed the experimentally observed varia-
tion within an arbitrarily chosen cutoff of 2% (Figure 6; Table 2,
the Correctness column). Among 5HT1B models, both first and
second top-ranking predictions were submitted by group Stock-
holm-Carlsson as their models #2 (Figure 8A) and #3, respec-
tively. The models contained no alignment errors. For model
#2, the TM and ECL2 backbone atoms were 1.82 A˚ and 4.34 A˚
from the answer, whereas model #3 was marginally closer in
the TM domain (TM backbone RMSD of 1.66 A˚). The receptor
prediction accuracy was at 0.86 SDs above the mean of the
model population. The geometry and the composition of the
binding pocket are among the best in the assessment (RMSDs
of 1.41 A˚ and 1.31 A˚ over the heavy atoms of the 19 pocket res-
idues, 1.2 A˚ and 1.07 A˚ for the 14 residues in the TM domain, and
less than 1.5 A˚ for the 3 ECL2 residues, 77% and 81% accuracy
in the pocket fingerprint prediction). The docked ligand featured
nonhydrogen atom RMSDs of 1.51 A˚ and 2.09 A˚ for the two
models, and reproduced 47% and 51% of the experimental
ligand-pocket atomic contacts. To derive their complex models,
the authors used the approach that has proved successful in the
previous assessment and in multiple GPCR modeling applica-
tions (Carlsson et al., 2011; Katritch and Abagyan, 2011; Katritch–1139, August 5, 2014 ª2014 Elsevier Ltd All rights reserved 1135
Figure 8. Highest Ranking Models of the
Four Targets in GPCR Dock 2013
The highest ranking models in each of the core
assessments 5HT1B (A), 5HT2B (B), SMO/LY-
2940680 (C), and SMO/SANT1 (D) are shown with
its group identifier.
Structure
2013 GPCR Modeling and Docking Assessmentet al., 2011, 2012; Mysinger et al., 2012; Weiss et al., 2013);
namely, they carried the refinement of their models in an iterative
manner evaluating, at each iteration, the enrichment of known
ligands in virtual screening.
The prediction of the ergoline core was only moderate in these
two top 5HT1B models (Table S2). The best ergoline core accu-
racy was achieved in model #1 by Schro¨dinger (0.72 A˚ RMSD,
65% of correct contacts) and model #3 by Copenhagen-Norn
(0.86 A˚ RMSD, 65% of correct contacts). Both demonstrate1136 Structure 22, 1120–1139, August 5, 2014 ª2014 Elsevier Ltd All rights reservedhighly accurate prediction for the pocket
residues. In the former model, the correct
ergoline core pose was ranked high by
taking into account conservation of
pocket residues between 5HT1B and
other ergoline-binding aminergic recep-
tors (see Supplemental Experimental
Procedures).
The most accurate 5HT2B model, War-
saw #3 (Figure 8B), contained no detect-
able alignment errors and had 2.12 A˚
backboneRMSDover the 191 TMdomain
residues and 2.69 A˚ RMSD over all non-
hydrogen atoms of the 23 binding site
residues. Seventy-six percent of the
pocket fingerprintwas identifiedcorrectly.
The ligand deviated by an RMSD of
only 1.05 A˚ from its crystallographic
pose and correctly reproduced 50%
of experimental ligand-pocket contacts.
The model was obtained using the
procedure implemented in the GPCRM
website (Modeler, loop refinement by Ro-
setta, model selection by DOPE, and
Rosetta total score) with subsequent
two-step ligand docking, GlideScore
scoring, and human expert analysis of
the complexes.
In contrast to the top model, 5HT2B
models ranking second, third, and fourth
(MerzPharma #3, #2, and #1, respec-
tively) featured one or more residue align-
ment shift errors in the top parts of TM he-
lices 4, and 7, resulting in the TM
backbone RMSD of 2.68 A˚, ECL2 RMSD
exceeding 9 A˚, and the protein prediction
z-score of more than 1 SD below the
model population mean. However, TMs
3, 5, and 6 containing most of the
ergotamine interactions were predicted
correctly. Consequently, in model #3,68% of the pocket fingerprint was correct; the ligand RMSD
from the target structure was as low as 1.15 A˚, and ligand pocket
contacts were reproduced with the accuracy of 45%. Moreover,
these models feature some of the most accurate predictions for
the ergoline core, with an RMSD of 0.66 A˚ and 73% of correct
contacts (Table S2). These predictions are closely followed by
threemodels from the Scandinavian teams (Stockholm-Carlsson
#2, Copenhagen-Norn #1, and Stockholm-Carlsson #4) with a
ligand RMSD below 2 A˚ and contact prediction accuracy
Structure
2013 GPCR Modeling and Docking Assessmentexceeding 50%. Along with, and possibly enabling, the ligand
prediction, Stockholm-Carlsson models feature high precision
in prediction of binding pocket residues not only in the TM
domain (RMSDs of 1.53–1.68 A˚) but also in ECL2 (RMSD of
2.3 A˚ for the four ECL2 residues in direct contact with the
ligand).
There was no correlation between the accuracy of ligand pre-
diction and the activation state of the receptor models. Top
ergotamine predictions were obtained in the models built by ho-
mology with thermostabilized turkey b1AR that (despite being
bound to full, partial, and biased agonists) is observed in an inac-
tive-like state (PDB IDs 2Y02, 2Y04, and 4AMJ, respectively), in-
verse agonist bound human b2AR (PDB 2RH1) and antagonist
bound M2 muscarinic receptor (PDB ID 3UON). All of these
models fully inherited the inactive-like states of their templates.
The top scoringmodel of the SMO/LY-2940680 complex (Van-
derbilt #3) (Figure 8C; Table 2) only weakly resembles the exper-
imental structure with the ligand deviating from the answer by as
much as 4.42 A˚ and no strong correct contacts (contact accu-
racy of 2%). Marginally better contact prediction was achieved
in the top-ranking models of SMO/SANT-1 complex (SMO/
SANT-1: GaTech #5, UMich-Zhang #3, SNU #5) (Figure 8D;
Table 2), probably owing to a more traditional TM location of
the SANT-1 binding pocket (7%, 11%, and 12% of contacts
captured, respectively). As with other assessment criteria, the
accuracy of target-template alignment appeared a prerequisite
for ligand pose prediction in SMO. Proper placement of selected
pocket residues allowed the authors to follow the docking proce-
dure with mutagenesis-guided manual ligand pose selection.
However, even when alignment in the pocket-defining helices
is largely ‘‘correct,’’ partial offsets and shifts of the helical back-
bone impact positioning of the interacting residues and ulti-
mately affect contact prediction.
DISCUSSION
The targets in the present assessment presented a new set of
challenges for the GPCR modelers. Despite high homology to
the previously determined structures, 5HT1B and 5HT2B com-
plexes with ergotamine were hard to predict because the latter
makes extensive (and different) contacts with the flexible
ECLs. These interactions could only be modeled with moderate
precision: the most accurate poses of ergotamine featured
RMSDs of 1–1.5 A˚ and about 50% of correct contacts. Only
3.3%–5% of experimentally solved complex structure pairs
deviate from each other as much as the best 5HT1B and 5HT2B
models deviate from the answers. This partial success correlates
with limited accuracy in the ECL predictions. In contrast, for the
small and rigid ergoline core that predominantly interacts with
the TM domain residues, the best prediction accuracy is compa-
rable to an 13–20 percentile of the experimental distribution,
with an RMSD as low as 0.64–0.67 A˚ and up to 73% of correct
contacts.
Most successful serotonin receptor predictions were derived
using homology modeling, often using the Modeler software
and multiple templates in the form of the available aminergic re-
ceptor structures. As in the previous assessment, the strategy of
selecting the models by their ability to recognize known ligands
among similar inactive molecules played out well. Some of theStructure 22, 1120top-ranking complexes were refined by molecular dynamics
simulations. Visual inspection and manual or semiautomatic
model selection using subfamily-specific residue contacts,
ligand SAR, and mutagenesis data also proved productive.
Many of the submitted models successfully captured the acti-
vation state of 5HT1B, but not the biased state of 5HT2B. Avail-
ability of structures in various functional states is a contributing
factor for this; however, the lack of correct predictions for
5HT2B highlights the need for either experimental determination
of multiple functional states of GPCRs or for the development of
reliable computational methods for their prediction.
The SMO structure presented a level of challenge previously
unseen in the GPCR Dock assessments, not only because of
its extremely low homology to the existing structures but also
because of its long ECLs, whose fold is unique among GPCR
structures solved to date. The present assessment highlighted
uncertainties in the target-template sequence alignment as the
critical bottleneck in distant homology modeling. It demon-
strated the advantage of composite approaches that incorporate
threading, fragment assembly, and energy-based refinement
(e.g., iterative threading assembly refinement, or I-TASSER)
(Roy et al., 2010; Wu et al., 2007) in finding the proper residue
correspondence. The growing number of GPCR structures in-
crease our understanding of the principles of dynamic intramo-
lecular packing in these proteins; such knowledge may promote
better methods for residue contact prediction (e.g., MemBrain)
(Yang et al., 2013a) and help in recognizing distant homology.
SMO assessment also showed that, while the alignment ambi-
guities can be tackled by modern algorithms, the structural ac-
curacy of the distant homologymodels is still in need of improve-
ment, especially in loop regions. Wise selection of targets for
experimental structure determination can help advance the
structural coverage of the GPCR superfamily and boost
elucidation of structure and function of the closer homologs by
computational methods.
EXPERIMENTAL PROCEDURES
Data Collection and Filtering
TheGPCRDock 2013model submission system and validation server were im-
plemented online at http://gpcr.scripps.edu/GPCRDock2013/ and http://ablab.
ucsd.edu/GPCRDock2013/modelValidator.cgi, respectively. Authors were re-
quested to submit up to fivemodelsper target. Allmodelswere analyzed for pro-
tein structure prediction accuracy but only thosewith nomajor steric clashes for
ligand docking accuracy.
Analysis of Alignment Accuracy
PDB structural templates were identified for all models by sequence-indepen-
dent structural alignment followed by superposition quality (Qsuper; Kufareva
and Abagyan, 2012) evaluation. Model-template TM domain residue corre-
spondencewas extracted and compared to the experimental structure-guided
alignment. Models for which PDB templates could not be unambiguously iden-
tified were excluded from this analysis.
Analysis of Protein Structure Prediction Accuracy
The protein molecule of each model was superimposed on to the backbone
Ca, C, and N atoms of the TM domain (residues 1.30–1.60, 2.37–2.64, 3.22–
3.54, 4.38–4.64, 5.35–5.64, 6.28–6.58, and 7.32–7.55 in Ballesteros-Weinstein
notation; Ballesteros and Weinstein, 1995) of the target structure using an
adaptive algorithm attenuating the contribution of farthest deviating structure
fragments (Abagyan and Kufareva, 2009; Bottegoni et al., 2009). The models
were assessed by calculating the RMSDs of their TM Ca, C, and N atoms–1139, August 5, 2014 ª2014 Elsevier Ltd All rights reserved 1137
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For 5HT receptors, model activation state was quantified by calculating the
rotation angles of TMs 6 and 7 with respect to a rigid block of TMs 3 and 4
as described in Supplemental Experimental Procedures.
With the same TM superimposition, backbone RMSD values were calcu-
lated for the model extracellular domains defined as follows:
d ECL1 = 110–119, ECL2 = 187–205, ECL3 = 337–348 in 5HT1B;
d ECL1 = 115–125, ECL2 = 193–214, ECL3 = 347–359 in 5HT2B; and
d ECL1 = 289–311, ECL2 = 378–396, ECL3 = 477–515 in SMO.
The disordered residues 191–196, 340–344 in 5HT1B, and 198–200 in 5HT2B
were omitted from the comparison.
Atomic Contact Strength Calculation
Contact strengths between the nonhydrogen atoms in the ligands and in the
binding pockets were calculated based on interatomic distances (d) as
described in (Kufareva and Abagyan, 2012; Kufareva et al., 2011): the strength
was assigned to 1 for d < dmin = 3.23 A˚, 0 for d > dmax = 4.63 A˚; and decreased
from 1 to 0 as a linear function of d for dmin < d < dmax. Ligand-pocket atom
pairs separated by d < dmin were assigned steric clash penalties calculated
as dmin/d  1; if the sum of all penalties in the model exceeded 3, the model
was classified as sterically impossible.
Binding Pocket Residue Identification Accuracy
Similarity between the predicted and the experimental pocket residue content
was assessed by comparing the contact strength fingerprints of the ligand on
the residue backbone and side chains as described in Supplemental Experi-
mental Procedures. Fingerprint prediction accuracy was calculated as the
average of recall and precision.
Binding Pocket Conformation
Similarity of the pocket residue conformations was evaluated by measuring
heavy atom RMSDs of the residues for which the ligand contact strength
fingerprint in the target structures exceeded 1:
d D129, I130, C133, T134, C199, V200, V201, S212, A216, W327, F330,
F331, S334, M337, L348, F351, D352, T355, and Y359 for 5HT1B/
ergotamine;
d L132, D135, V136, S139, T140, V208, L209, T210, K211, F217, M218,
G221, A225, W337, F340, F341, N344, L347, V348, Q359, L362, E363,
and V366 for 5HT2B/ergotamine;
d N219, L221, M230, W281, M301, D384, V386, S387, F391, Y394, K395,
R400, H470, Q477, W480, E481, F484, P513, E518, N521, and L522 for
SMO/LY-2940680; and
d M230, F274, W281, L325, M326, V329, V386, S387, F391, Y394, I408,
V463, T466, H470, E518, N521, L522, M525, and T528 for SMO/
SANT-1.
RMSDwasmeasured following the optimal TM domain superimposition and
taking residue symmetry into account. TM domain superimposition was cho-
sen over direct binding pocket superimposition for several reasons: (1) the
arbitrariness of the binding pocket definition; (2) the impossibility of defining
it in a uniform way between different receptors and between receptors and
models; (3) the deficiency of superimposition concept, which is influenced
by outliers (more so in the case of binding pocket superimposition); and (4)
for consistency with previous GPCR Dock assessments.
Ligand Position and Conformation
RMSD of the ligand nonhydrogen atoms from their counterparts in the target
structure was determined after the optimal TM domain superimposition. Inter-
nal ligand symmetry was taken into account.
Ligand Atomic Contacts
Contact prediction accuracy was evaluated by comparing contact strengths
for all ligand-pocket atom pairs observed in the model with those in the target
structure, as described in (Kufareva and Abagyan, 2012; Kufareva et al., 2011)
(see also Supplemental Experimental Procedures). Ligand and side chain sym-1138 Structure 22, 1120–1139, August 5, 2014 ª2014 Elsevier Ltd Almetry was taken into account. Contact prediction accuracy was calculated as
the average of recall and precision.
Evaluation of Model Correctness in Context of Expected
Experimental Variation
Expected ligand RMSD and contact variation among the experimental struc-
tures were analyzed and approximated by an analytical function as described
in Supplemental Experimental Procedures. For each model, its calculated
ligand RMSD and contact prediction accuracy were compared to this distribu-
tion. The percentile of the experimental pairs with at least as high RMSD or at
least as low contact accuracy was reported as ‘‘correctness’’ and used for the
final model ranking.
Supplemental Materials
Summaries of protein and ligand prediction accuracies for all GPCR Dock
2013 models are provided as Tables S1 and S2, respectively. Details of model
analysis and descriptions of the methods used by the participating groups are
given in the Supplemental Experimental Procedures. All GPCR Dock 2013
models can be interactively viewed or downloaded from the assessment result
website at http://ablab.ucsd.edu/GPCRDock2013/.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
Supplemental Methods from 2013 GPCR Dock participants, one figure, and
two tables and can be found with this article online at http://dx.doi.org/10.
1016/j.str.2014.06.012.
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